Comparative Pharmacology
Head-to-head clinical analysis: AQUAPHYLLIN versus KAINAIR.
Peer-Reviewed Evidence
Head-to-head clinical analysis: AQUAPHYLLIN versus KAINAIR.
AQUAPHYLLIN vs KAINAIR
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Phosphodiesterase-3 (PDE3) inhibitor with additional adenosine receptor antagonism and weak inhibition of phosphodiesterase-4 (PDE4). Increases intracellular cAMP and cGMP, leading to bronchodilation and anti-inflammatory effects.
Kainair is a selective agonist for kainate receptors, which are ionotropic glutamate receptors. It depolarizes neurons by increasing sodium and calcium conductance, leading to excitatory neurotransmission and neurotoxicity at high doses.
300 mg orally every 6 hours as needed for acute asthma exacerbation; for chronic maintenance, 300 mg orally every 8 hours.
25 mg subcutaneously three times daily.
None Documented
None Documented
Terminal elimination half-life: 3-5 hours in healthy adults; prolonged to 8-12 hours in neonates and up to 30 hours in cirrhosis.
3-5 hours, prolonging in renal impairment (up to 12-18 hours in GFR <30 mL/min).
Renal: 90-95% unchanged; biliary/fecal: <5%.
Primarily renal (approximately 90% unchanged drug within 24 hours), with minor biliary/fecal elimination (<10%).
Category C
Category C
Bronchodilator
Bronchodilator